Tricuspid regurgitation

furosemide vs placebo · Cardiac Output

55 studies (92,019 patients) provide low-certainty evidence for benefit of furosemide for Cardiac Output in Severe tricuspid valve regurgitation.

transvenous lead extraction (tle) vs placebo

5 studies (67,405 patients) provide low-certainty evidence against benefit of transvenous lead extraction (tle) for the outcome in lead-related tricuspid valve dysfunction.

transcatheter tricuspid valve intervention (ttvi) vs placebo · All-Cause Mortality

2 studies (3,826 patients) provide low-certainty evidence for benefit of transcatheter tricuspid valve intervention (ttvi) for All-Cause Mortality in Tricuspid Valve Insufficiency.

left bundle branch area pacing (lbbap) vs placebo

2 studies (214 patients) provide low-certainty evidence for benefit of left bundle branch area pacing (lbbap) for the outcome in Tricuspid Valve Insufficiency.

pantoprazole vs heparin, porcine

2 studies (120 patients) provide low-certainty evidence for benefit of pantoprazole for the outcome in Severe tricuspid valve regurgitation.

leadless pacemaker vs placebo

2 studies (65 patients) provide low-certainty evidence against benefit of leadless pacemaker for the outcome in Tricuspid Valve Insufficiency.

transcatheter asd closure vs placebo

2 studies (200 patients) provide insufficient evidence with mixed findings regarding transcatheter asd closure for the outcome in Ostium secundum atrial septal defect.

furosemide vs placebo · Cardiac Output

transcatheter tricuspid valve intervention (ttvi) vs placebo · All-Cause Mortality

transcatheter tricuspid valve intervention (ttvi) vs placebo · All-Cause Mortality